IND-directed development of antiviral therapies to combat diseases of pandemic potential
Active Awarded Last action
- Contract number
- 75N91022F00010
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $16,869,382
Award facts
- Contract value 100% obligated
- $16,869,382.00 Current and potential, with all options
- Completion date 85% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21703, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | -$1,843,960 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $3,377,004 | |
| Original award | $15,336,338 |
About this award
The National Center for Advancing Translational Sciences issued a delivery order to Leidos Biomedical Research Inc. on July 27, 2022, with a ceiling value of $16.9 million for industry-directed development of antiviral therapies to combat diseases of pandemic potential.
Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC) contractor subsidiary of Leidos Holdings, Inc., serving the National Institutes of Health and National Cancer Institute. Place of performance is Frederick, MD. The order is priced on a cost-plus-fixed-fee basis with an ultimate completion date of July 26, 2027.
Service Contract Inventory reporting shows government-invoiced labor of $396 thousand in FY2022 (32 contractor hours), $32 thousand in FY2023 (341 contractor hours), and $54 thousand in FY2024 (770 contractor hours), reflecting 0.4 FTEs in the most recent fiscal year. Derived government-paid hourly rates declined from $12,360.67 per hour in FY2022 to $70.33 per hour in FY2024. The prime self-performed all reported hours; no subcontractors were reported in SCI activity.
Quick answers
Who was awarded contract 75N91022F00010?
75N91022F00010 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on July 27, 2022.
How much is contract 75N91022F00010 worth?
The government has obligated $16,869,382 on 75N91022F00010.
Which agency awarded contract 75N91022F00010?
National Cancer Institute (National Institutes of Health) awarded 75N91022F00010, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N91022F00010 an order under another contract?
Yes. 75N91022F00010 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91022F00010 competed?
The extent of competition for 75N91022F00010 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award